

DESCRIPTION

Species Reactivity	Mouse
Specificity	Detects mouse PIR-A and mouse PIR-B in direct ELISAs.
Source	Monoclonal Rat IgG _{2A} Clone # 404127
Purification	Protein A or G purified from hybridoma culture supernatant
Immunogen	Mouse myeloma cell line NS0-derived recombinant mouse PIR-A1 Gly24-Met650 Accession # A2NTJ8
Conjugate	Alexa Fluor 594 Excitation Wavelength: 590 nm Emission Wavelength: 617 nm
Formulation	Supplied 0.2 mg/mL in a saline solution containing BSA and Sodium Azide. See Certificate of Analysis for details. *Contains <0.1% Sodium Azide, which is not hazardous at this concentration according to GHS classifications. Refer to the Safety Data Sheet (SDS) for additional information and handling instructions.

APPLICATIONS

Please Note: Optimal dilutions should be determined by each laboratory for each application. *General Protocols* are available in the *Technical Information* section on our website.

	Recommended Concentration	Sample
Flow Cytometry	0.25-1 µg/10 ⁶ cells	Mouse B220 ⁺ splenocytes

PREPARATION AND STORAGE

Shipping	The product is shipped with polar packs. Upon receipt, store it immediately at the temperature recommended below.
Stability & Storage	Protect from light. Do not freeze. <ul style="list-style-type: none"> 12 months from date of receipt, 2 to 8 °C as supplied.

BACKGROUND

Paired Ig-like Receptor-B (PIR-B) is a 125 kDa type I transmembrane glycoprotein with six Ig-like domains in its extracellular domain (ECD) and four ITIM-like sequences in its cytoplasmic domain. The ECD of PIR-B is highly homologous to the ECDs of multiple mouse PIR-A receptors (92-99% amino acid sequence homology), which have short cytoplasmic tails lacking ITIM motifs. PIR-A receptors have a charged residue in their transmembrane domain that facilitates interaction with ITAM-containing adaptor molecules. Whereas PIR-A receptors deliver activation signals, PIR-B can inhibit receptor-mediated activation signaling. PIR-A and PIR-B have been shown to bind various mouse MHC class I molecules. They have been proposed to be orthologs of human leukocyte immunoglobulin-like receptors.

PRODUCT SPECIFIC NOTICES

This product is provided under an agreement between Life Technologies Corporation and R&D Systems, Inc, and the manufacture, use, sale or import of this product is subject to one or more US patents and corresponding non-US equivalents, owned by Life Technologies Corporation and its affiliates. The purchase of this product conveys to the buyer the non-transferable right to use the purchased amount of the product and components of the product only in research conducted by the buyer (whether the buyer is an academic or for-profit entity). The sale of this product is expressly conditioned on the buyer not using the product or its components (1) in manufacturing; (2) to provide a service, information, or data to an unaffiliated third party for payment; (3) for therapeutic, diagnostic or prophylactic purposes; (4) to resell, sell, or otherwise transfer this product or its components to any third party, or for any other commercial purpose. Life Technologies Corporation will not assert a claim against the buyer of the infringement of the above patents based on the manufacture, use or sale of a commercial product developed in research by the buyer in which this product or its components was employed, provided that neither this product nor any of its components was used in the manufacture of such product. For information on purchasing a license to this product for purposes other than research, contact Life Technologies Corporation, Cell Analysis Business Unit, Business Development, 29851 Willow Creek Road, Eugene, OR 97402, Tel: (541) 465-8300. Fax: (541) 335-0354.